Advanced search
Start date
Betweenand

Evaluation of intestinal dysbiosis in patients with Hashimoto thyreoiditis and correlation with inflammatory cytokines

Grant number: 17/07444-2
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): July 01, 2017
Effective date (End): June 30, 2018
Field of knowledge:Biological Sciences - Immunology
Principal Investigator:Gislane Lelis Vilela de Oliveira
Grantee:Leonardo César de Freitas Cayres
Home Institution: Faculdade de Ciências da Saúde de Barretos Dr Paulo Prata (FACISB). Barretos , SP, Brazil

Abstract

In humans, over one hundred trillion microorganisms, mainly bacteria, colonize the oral-gastrointestinal tract, and the vast majority of these reside in the distal gut and was termed microbiota. The most important microbiota's contributions for the host include carbohydrates digestion and fermentation, vitamin production, mucosal-associated lymphoid tissues development, immune responses polarization and prevent pathogens colonization. However, when this mutualistic relationship between host and microbiota is interrupted, the intestinal microbiota may cause or contribute to the development of infectious diseases, inflammatory and autoimmune diseases. Therefore, the aim of this study is to evaluate intestinal dysbiosis in patients with Hashimoto thyreoiditis (HT) and to correlate with serum concentrations of inflammatory cytokines. Patients and control subjects will be included in the health center from Health Department from Barretos. The study was approved by the Ethics Committee (1359/2017), and patients and controls will sign the informed consent and answer a socio-epidemiological questionnaire. Fecal samples are collected by own individuals or families in universal collectors. Clinical data such as metabolic syndrome, weight gain, alopecia, fatigue, neurological manifestations, constipation, anti-thyroperoxidase, anti-thyroglobulin, anti-TSH receptor antibody and treatment will be recorded. Bacterial DNA is extracted by using commercial kit and the microbiota characterization will be performed by real-time PCR. The quantification of inflammatory cytokines will be done by ELISA assays. The results of the intestinal microbiota of patients and controls will be analyzed by using Mann-Whitney test and correlations of microbiota results with clinical and cytokines data will be assessed by Spearmans' test. We expect to find differences in the composition of the intestinal microbiota of patients with HT compared with healthy subjects and possible correlations with clinical data and inflammatory cytokines. Further studies are necessary, and possibly in the future, immunomodulatory probiotics may aid in the treatment of HT. (AU)